Literature DB >> 29032751

Development of Drug Targeting and Delivery in Cervical Cancer.

Urvashi Aggarwal1, Amit Kumar Goyal1, Goutam Rath1.   

Abstract

Cervical cancer is the second most common cancer in women. Standard treatment options available for cervical cancer include chemotherapy, surgery and radiation therapy associated with their own side effects and toxicities. Tumor-targeted delivery of anticancer drugs is perhaps one of the most appropriate strategies to achieve optimal outcomes from the treatment and improve the quality of life. Recently nanocarriers based drug delivery systems owing to their unique properties have been extensively investigated for anticancer drug delivery. In addition to that addressing the anatomical significance of cervical cancer, various local drug delivery strategies for the cancer treatment are introduced like: gels, nanoparticles, polymeric films, rods and wafers, lipid based nanocarrier. Localized drug delivery systems allow passive drug targeting results in high drug concentration at the target site. Further they can be tailor made to achieve both sustained and controlled release behavior, substantially improving therapeutic outcomes and minimizing side effects. This review summarizes the meaningful advances in drug delivery strategies to treat cervical cancer. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Cervical cancer; drug delivery system; drug targeting; localized delivery; nanocarriers; parenteral route.

Mesh:

Substances:

Year:  2018        PMID: 29032751     DOI: 10.2174/1568009617666171009165105

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  4 in total

1.  Local delivery of arsenic trioxide nanoparticles for hepatocellular carcinoma treatment.

Authors:  Jian Hu; Yi Dong; Li Ding; Yang Dong; Zhihua Wu; Wenping Wang; Ming Shen; Yourong Duan
Journal:  Signal Transduct Target Ther       Date:  2019-09-06

2.  Human endoglin-CD3 bispecific T cell engager antibody induces anti-tumor effect in vivo.

Authors:  Liping Zhong; Wei Shi; Lu Gan; Xiuli Liu; Yu Huo; Pan Wu; Zhikun Zhang; Tao Wu; Hongmei Peng; Yong Huang; Yongxiang Zhao; Yulin Yuan; Zhiming Deng; Hongliang Tang
Journal:  Theranostics       Date:  2021-04-19       Impact factor: 11.556

3.  5FU-loaded PCL/Chitosan/Fe3O4 Core-Shell Nanofibers Structure: An Approach to Multi-Mode Anticancer System.

Authors:  Mehdi Hadjianfar; Dariush Semnani; Jaleh Varshosaz; Sajad Mohammadi; Sayed Pedram Rezazadeh Tehrani
Journal:  Adv Pharm Bull       Date:  2021-09-29

Review 4.  Analysis of the Exposure of Organisms to the Action of Nanomaterials.

Authors:  Anita Staroń; Olga Długosz; Jolanta Pulit-Prociak; Marcin Banach
Journal:  Materials (Basel)       Date:  2020-01-12       Impact factor: 3.623

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.